Searched for
ABBOTT AND MEDTRONIC
Dexcom plunges as revenue forecast cut spooks investorsDexcom shares plummeted over 40% due to a revenue forecast cut linked to a problematic salesforce restructuring. The changes led to fewer n...- India looks to lure more than 1,000 American companies out of ChinaTrump’s move to blame China for the Covid-19 outbreak is expected to worsen global trade ties.
- NPPA not to stop withdrawal of stents from marketThe authority had asked the companies to consider options for price revision before deciding to withdraw their products from the market.
- Local stent companies catch fancy of PE playersAs multinational stent makers ponder their prospects in India after price controls introduced this year, their local rivals have popped up ...
- Diabetes devices move from sharp fingerpricks to slick techFor the winners, the potential market is huge. Diabetes device sales totaled $14 billion in the US last year.
- Domestic stent makers gain on the back of price capsThis year, domestic stent firms are aiming for 60 per cent of the market estimated to be Rs 1,200 crore now due to a drop in the average pr...
- Government to revisit stent price control in FebruaryThe government is expected to hold discussions to decide on these requests only in February, a year after it first capped prices of these l...
- After dissolvable stent 'Absorb', Abbott moves to withdraw 'Xience Alpine'Abbott publicly announced intentions to stop global sales of dissolvable scaffold ‘Absorb’, which has been mired in controversy for risks r...
- NPPA rejects Abbott, Medtronic's request to withdraw latest stentsThe companies sought to withdraw Abbott’s Xience Alpine and Absorb, and Medtronic’s Resolute Onyx stents after NPPA slashed their prices by...
- Stent Abbott wants to pull out is `identical' to othersAbbott is selling its drug eluting stents, including the Xience Alpine, for the equivalent of Rs 29,000 to Rs 33,000 in many European count...
- Centre cracks whip, no stent can be withdrawn, for nowThe department of pharmaceuticals (DoP) said it had come across reports regarding shortage of coronary stents in the market and in hospital...
- Government invokes emergency clause to maintain supply of stentsThe move comes in the wake of various multinationals, including Abbott and Medtronic, seeking permission to withdraw some of their products...
- Three MNC pharma companies want to recall its new generation stents from IndiaIt's not clear if firms can withdraw their products as the Department of Pharmaceuticals had recently prevented stent makers from taking th...
- Stent price control shows India not open for businessAddition of stents to essential list contrary to international norms, says US embassy official.
- Indian cardiac stents as expensive as imports: MNC associationIndian stents are not drastically cheaper to imported stents, says the Medical Technology Association of India
- JBIMS completes summer placements with top stipend of Rs 3.5 lakh, 11% increase in average stipendA sharp rise in the number of conglomerates and manufacturing companies visiting the campus led to a two-fold increase in the number of off...
- Capping stent prices will halt new launches, says industryThe process may require the drug pricing watchdog to look at a set of separate parameters for these devices as compared to that for drugs.
- Jamnalal Bajaj Institute wraps up summer placements with an average stipend of Rs 91,000Jamnalal Bajaj Institute of Management Studies has wrapped up its summer placements for the 2012-14 batch with an average stipend of Rs 91,...
- Rivals to benefit as J&J exits from heart stentsThe decision of Johnson&Johnson to stop making its popular drug eluting stent has opened up new opportunities for competitors Abbott & Bost...
- FDA plans stricter norms for stentsUS regulators may recommend stricter testing standards for cardiac stents to ensure that the devices are safer than those now available, ac...
Load More
